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ABSTRACT
It is well known that activating mutations in the KRAS and NRAS genes are 
associated with poor response to anti-EGFR therapies in patients with metastatic 
colorectal cancer (mCRC). Approximately half of the patients with wild-type (WT) 
KRAS colorectal carcinoma do not respond to these therapies. This could be because 
the treatment decision is determined by the mutational profile of the primary tumor, 
regardless of the presence of small tumor subclones harboring RAS mutations in 
lymph nodes or liver metastases. We analyzed the mutational profile of the KRAS, 
NRAS, BRAF and PI3KCA genes using low-density microarray technology in samples of 
26 paired primary tumors, 16 lymph nodes and 34 liver metastases from 26 untreated 
mCRC patients (n=76 samples). The most frequent mutations found in primary tumors 
were KRAS (15%) and PI3KCA (15%), followed by NRAS (8%) and BRAF (4%). 
The distribution of the mutations in the 16 lymph node metastases analyzed was 
as follows: 4 (25%) in KRAS gene, 3 (19%) in NRAS gene and 1 mutation each in 
PI3KCA and BRAF genes (6%). As expected, the most prevalent mutation in liver 
metastasis was in the KRAS gene (35%), followed by PI3KCA (9%) and BRAF (6%). 
Of the 26 cases studied, 15 (58%) displayed an overall concordance in the mutation 
status detected in the lymph node metastases and liver metastases compared with 
primary tumor, suggesting no clonal evolution. In contrast, the mutation profiles 
differed in the primary tumor and lymph node/metastases samples of the remaining 
11 patients (48%), suggesting a spatial and temporal clonal evolution. We confirm 
the presence of different mutational profiles among primary tumors, lymph node 
metastases and liver metastases. Our results suggest the need to perform mutational 
analysis in all available tumor samples of patients before deciding to commence anti-
EGFR treatment.
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INTRODUCTION
Sporadic colorectal cancer (sCRC) is the third most 
frequently diagnosed cancer worldwide and the third most 
common cause of cancer-related death [1]. Approximately 
300,000 new cases of sCRC are reported each year and 
200,000 patients (67% of cases) die from cancer-related 
complications, most of them as a consequence of the 
metastatic process (i.e., mostly liver metastasis) [2]. In 
recent years, therapies with anti-EGFR agents targeting 
the metastatic process have improved sCRC outcome, 
but only a subset of selected patients benefit from these 
treatments [3]. It is well known that activating mutations 
in the KRAS (35% of cases) and NRAS (1-3%) genes are 
associated with poor response to anti-EGFR therapies, 
which rules out anti-EGFR-directed therapy as an option 
for these patients [4]. The BRAF V600E mutation occurs 
in 10-15% of metastatic CRC (mCRC) cases [5], but does 
not predict resistance to anti-EGFR therapies. However, 
BRAF mutation is a strong marker of poor prognosis in 
mCRC [5]. Genetic events in additional nodes of the 
EGFR pathway, such as PI3KCA exon 20 mutations, may 
also confer resistance to anti-EGFR therapies [6, 7]. In 
addition, up to 50% of the patients with wild-type (WT) 
KRAS colorectal carcinoma do not respond to this therapy, 
possibly because the decision to treat is determined by 
the mutational profile of the primary tumor, regardless 
of the presence of small tumor subclones harboring RAS 
mutations in lymph nodes or liver metastases. The most 
recent European Society for Medical Oncology (ESMO) 
guidelines for the management of patients with metastatic 
sCRC recommend that RAS mutation testing be performed 
in either primary tumor or liver metastasis samples, 
tissue from other metastatic sites, such as lymph node 
metastases, may be used if neither a primary tumor nor a 
liver metastasis sample are available [8]. Most studies have 
employed primary tumor samples from sCRC patients to 
define the mutations of KRAS, NRAS, BRAF and PI3KCA 
genes [9, 10]. However, apparently contradictory results 
have been reported about the concordance between the 
mutational status of these genes in primary tumors and 
their corresponding liver metastases. Thus, while several 
papers report full concordance between primary tumors 
and liver metastases [11–13], others have found up to 31% 
[14] of discrepancies. In addition, studies comparing the 
mutation distribution in primary tumors and lymph node 
metastases in the same patient are scarce [15, 16]. Our 
research group has recently provided detailed information, 
obtained from the use of FISH and high-density single-
nucleotide polymorphism (SNP) array techniques, about 
the clonal heterogeneity and genetic diversity within a 
given tumor, whereby different abnormalities coexist 
in the same tumor sample (intratumoral heterogeneity) 
[17]. However, the precise patterns of intratumoral clonal 
evolution estimated from the mutational profile of the 
genes associated with the EGFR signaling pathway, and 
their relationship with the neoplastic clones present in 
primary vs. lymph node metastases vs. metastatic tumor 
samples (intertumoral heterogeneity) remain controversial. 
It is important to identify intratumoral and intertumoral 
heterogeneity since both could affect the response to 
targeted therapies.
Here, we analyzed the mutational profile of KRAS, 
NRAS, BRAF and PI3KCA genes using low-density 
microarray technology in samples of 26 paired primary 
tumors, 16 lymph nodes and 34 liver metastases from 26 
untreated mCRC patients (n=76 samples). Our aims were: 
(1) to identify mutational profile differences between 
paired primary vs. lymph node metastases vs. multiple 
liver metastases samples that might explain resistance to 
therapies in WT primary tumor, and (2) to describe the 
spatial intratumoral heterogeneity and temporal clonal 
evolutionary processes.
RESULTS
Mutation frequencies and intratumoral and 
intertumoral genetic heterogeneity
In all DNA samples a successful amplification of 
the mutant or WT allele was obtained by PCR. Mutations 
in at least one of the analyzed genes and/or one tumor 
sample (primary tumor, lymph node metastases or 
liver metastases) were found in 13 patients (50% of 
cases). Overall, 37 mutations were detected in the 76 
tumor samples (11 in primary tumors, 9 in lymph node 
metastases and 17 in liver metastases). The mutations 
found in primary tumors were most frequently of the 
KRAS and PI3KCA genes (each with 4/26 cases; 15%), 
followed by those of the NRAS (2/26; 8%) and BRAF 
(1/26; 4%) genes. The mutations in the 16 lymph node 
metastases were distributed as follows: 4 (25%) in KRAS, 
3 (19%) in NRAS and 1 in each of the PI3KCA and BRAF 
genes (6%). As expected, the most prevalent mutation 
in liver metastases was in the KRAS gene (12/34; 35%), 
followed by the PI3KCA (3/34; 9%) and BRAF (2/34; 6%) 
genes.
Detailed information about each patient and 
their sample mutation profile is provided in Table 1. 
Of the 26 cases studied, 15 (58%) displayed an overall 
concordance in the mutation status detected in the lymph 
node metastases and liver metastases compared with 
primary tumor (13 cases were WT and the other two had 
a KRAS mutation: G12D and G12V), suggesting no clonal 
evolution. In contrast, in the other 11 patients (42%), the 
mutation profile differed between the primary tumor and 
lymph node/metastasis samples, suggesting intertumoral 
clonal evolution.
Figure 1 summarizes the hypothetical pathways of 
intratumoral and intertumoral clonal evolution detected in 
these samples. The mutation profile identified in primary 
tumors was considered the founder clone portrait, the 
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Table 1: Details of the clinical, biological and genetic characteristics and type of sample studied of each individual 
metastatic colorectal cancer patient analyzed in this study (n=26)



















node LM #1 LM #2 LM #3 LM #4
1 M 60 29.4 Right colon Well 3.8 T3N0M1 No No WT - WT - - -
2 M 74 1484 Right colon Well 4 T3N2M1 No No WT WT WT - - -
3 M 76 44 Right colon Moderate 5.5 T3N1M1 No Lung WT WT
KRAS 
(G12D) - - -






(G12D) - - -
5 M 69 7.6 Left colon Well 3 T3N0M1 Yes Lung WT - WT - - -
6 M 64 256 Left colon Well 7 T3N0M1 No No WT - WT - - -








































10 M 77 244.9 Left colon Well 5.5 T3N1M1 No No WT - WT
* - - -
11 M 61 1.2 Left colon Moderate 3 T2N0M0 No No WT - WT
* - - -






(G12V) - - -
13 F 58 501 Left colon Moderate 5 T4N2M1 Yes Lung WT WT WT - - -
14 M 72 45.4 Left colon Poorly 4 T3N1M1 Yes No WT WT WT - - -






(V600E) - - -
16 M 66 3.7 Rectum Well 8.5 T3N0M0 No No WT - WT* - - -
17 F 62 139 Rectum Well 4 T3N0M1 No No WT - WT - - -
18 M 74 6.4 Rectum Well 5 T3N1M0 No No BRAF (V600E) WT
KRAS 
(G12A) - - -
19 M 75 589.2 Rectum Well 4 T3N1M0 No No WT PI3K (E545K/D) WT
* - - -
20 M 77 58.3 Rectum Well 9 T3N1M1 No No WT WT PI3K (E545K/D) - - -
21 M 63 23.2 Rectum Well 7 T3N2M1 No No WT WT WT - - -
22 M 64 5.4 Rectum Well 7 T4N0M0 No No WT - WT* - - -
23 M 79 0.8 Rectum Well 5 T4N0M1 No No KRAS (G12V) -
KRAS 
(G12V) - - -
24 F 76 149.8 Rectum Moderate 2.5 T3N1M1 No No WT WT WT WT WT WT
25 F 49 6.8 Rectum Moderate 6.5 T3N1M1 No No PI3K (E545K/D) WT
KRAS 
(G12V) - - -
26 M 74 110 Rectum Moderate 5 T4N0M1 No No NRAS (Q61H) - WT - - -
Abbreviations: M: male; F: female; CEA: carcinoembryonic antigen; PT: primary tumor; LM: different liver metastases developed in each patient; well: well-differentiated 
adenocarcinoma; moderate: moderately differentiated adenocarcinoma; poor: poorly differentiated adenocarcinoma; WT: wild-type; -: not applicable. *metachronous sample.
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Figure 1: Intratumoral and intertumoral mutation heterogeneity of primary colorectal carcinomas as determined 
by the presence of different mutation status for KRAS, NRAS, PIK3 and BRAF genes. Only those patients with mutation 
heterogeneity across the three tumor samples in one or more of the four examined genes are shown (n=11). A detailed description of all 
patients (n=26) and samples (number and type) analyzed can be found in Table 1. Each circle represents a tumor cell clone detected in the 
sample analyzed. Tissue origin in represented by the following pictures:  for the primary tumor;  lymph node;  liver metastasis. If 
more than one sample per tissue was studied it is mentioned in the figure (n= number of samples).
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most common profile being characterized by the presence 
of two clones (n=6), one of which harbored a mutation 
in PI3KCA (n=3), BRAF (n=1) or NRAS (n=2), and the 
other one being a WT clone. However, there were four 
cases where the primary tumor was characterized by the 
presence of only one clone (n=4) —either a WT clone 
(n=3) or a mutated KRAS clone (n=1)— and another 
patient with three clonal populations in the primary 
tumor (a WT subclone and two subclones with KRAS 
and PI3KCA mutations). With respect to the lymph node 
metastasis status, all cases presented with one clonal 
population; four cases were WT and six cases harbored 
different mutations. Of the latter mutated cases, two 
were characterized by the presence of a KRAS mutation, 
and there were single cases each of an NRAS mutation, 
simultaneous BRAF/NRAS mutations, a KRAS/NRAS 
mutation, and a PI3KCA mutation. Only one of the six 
cases had a mutation concordant with its primary tumor 
sample.
Considering the liver metastases, nine cases showed 
one clonal population, the most frequent being a KRAS-
mutated clone (n=5), followed by a WT clone (n=2), and 
BRAF (n=1) and PI3KCA (n=1) mutated clones. The two 
other cases had two clonal populations, the first with 
KRAS and PI3KCA mutated clones, and the second with 
one clone featuring a KRAS plus PI3KCA mutation and a 
second clone exhibiting a BRAF mutation.
Clonal evolution patterns
Two patterns of clonal evolution are plausible from 
the evidence of these samples: (1) no evolution, when the 
mutation profile in the primary tumor is the same as in the 
lymph node metastases or liver metastasis sample and (2) 
linear evolution, when the primary tumor profile acquires 
additional mutations during the process of migration to the 
lymph node or liver.
Regarding the transition from primary tumor to 
the lymph node metastases, five cases showed no clonal 
evolution (patients 3, 7, 18, 20 and 25) and five cases 
displayed linear evolution (patients 8, 9, 12, 15 and 19). 
For the cases of primary tumor to liver metastasis, no 
evolution pattern was observed in three (patients 9, 19 and 
26), and linear evolution was detected in seven of them 
(patients 3, 7, 12, 15, 18, 20 and 25). One case showed a 
mixed pattern (patient 8), whereby a WT clone acquired 
a KRAS mutation that was present in two liver metastasis 
samples (linear evolution) and another PI3KCA-mutated 
clone without any evolution.
DISCUSSION
Approximately 30% of patients with sCRC have 
KRAS mutations and are resistant to EGFR inhibitors, 
and up to 50% of metastatic colorectal cancer (mCRC) 
cases with KRAS wild-type (WT) do not respond to anti-
EGFR therapies [18, 19]. The presence of a KRAS WT 
genotype in the primary tumors from mCRC patients does 
not guarantee any benefit from EGFR inhibitors [19], so 
the availability of other factors that could predict treatment 
resistance is of great importance for identifying which 
KRAS WT mCRC patients will be non-responders and 
who will develop resistance after an initial response.
The aim of this study was to describe the 
intertumoral heterogeneity of mCRC tumors through 
the mutation frequency of four key driver genes (KRAS, 
NRAS, PIK3CA and BRAF) in 76 samples from 26 
untreated mCRC patients at diagnosis corresponding 
to 26 primary tumors, 16 lymph node metastases and 
34 liver metastasis samples and then to establish the 
intratumoral pathways of clonal evolution. To the best of 
our knowledge, this is the first study to propose and test a 
hypothetical model of intratumoral and intertumoral clonal 
evolution of the most frequently altered genes (KRAS, 
NRAS, PIK3CA and BRAF), comparing the mutational 
status in liver metastases, lymph node metastases versus 
paired primary colorectal tumors, using low-resolution 
arrays. Overall, our results show that colorectal cancers 
are highly heterogeneous tumors at the intratumoral and 
intertumoral genetic levels, which probably affects the 
response to targeted anti-EGFR agents.
Primary tumor heterogeneity is a well-recognized 
challenge to personalized medicine [20–22]. Previous 
studies have revealed clonal heterogeneity of KRAS 
mutations within primary mCRC [23, 24] and regarding 
the concordance in mutation status between primary 
tumors and metastatic deposits [25, 26]. However, 
mutational heterogeneity across synchronous deposits 
and lymph node metastases is not well described. Taking 
KRAS mutations as an example, some studies showed 
100% concordance between primary CRC tumors and 
paired metastases [12, 13], while others reported 4-30% 
discordance [14, 15]. Losi et al. [11] studied primary 
tumors and paired metastases from 35 patients, and found 
that KRAS mutations were present in 71% of cases with 
100% concordance, even in the local recurrences of the 
same patient. However, the literature suggests an incidence 
of KRAS mutations in approximately 45% of cases with 
mCRC [9, 27, 28]. In addition, the series analyzed by 
Knijn et al. (n=305 patients) showed 96% concordance in 
the KRAS gene status between primary tumor and paired 
liver metastases [29]. This finding is consistent with 
KRAS mutations mostly occurring as an early molecular 
event. On the other hand, there is increasing evidence 
of a degree of discordance in the KRAS mutational 
status between different tumoral samples from the same 
patient. Recently, Jeantet et al. [30] reported that 33% 
of cases with spatial intratumoral heterogeneity for RAS 
mutations coexisted within the same tumor with KRAS 
and/or NRAS mutated and WT zones. Kosmidou et al. 
[31] found similar intratumoral heterogeneity of KRAS 
mutations (44% discordance) when they compared tumor 
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center and tumor periphery. Al-Mulla et al. [16] analyzed 
KRAS status in 26 liver metastases and 31 lymph node 
samples and detected an overall discordance rate of 19% 
in the two subgroups compared with the primary tumor. 
Furthermore, the discordance reached 30% in the series 
analyzed by Albanese et al. [14]. Likewise, Miranda et 
al. [32] found different rates of KRAS mutations in lymph 
nodes (19%), liver metastases (38%) and primary tumors 
(32%) in 101 sCRC patients. The lower mutation rate in 
lymph nodes compared with primary tumors may indicate 
that neoplastic cells colonizing lymph nodes leave the 
primary tumor before KRAS alterations occur, or, if it is 
assumed that the primary tumor comprises different cell 
clones, one of these clones is responsible for survival and 
proliferation in the cells of the primary site. On the other 
hand, the presence of higher rates of KRAS mutations 
in liver metastases can be explained by the gradual 
acquisition of mutations as a secondary alteration during 
disease progression.
Other genes involved in the EGFR signaling 
pathway (NRAS, BRAF and PIK3CA) have been widely 
studied in primary sCRC. Mao et al. in their review and 
meta-analysis [26], examined the concordance of KRAS, 
BRAF, and PIK3CA mutational status between primary 
tumors and metastases, finding high concordance rates 
among liver metastases with primary tumor, but low 
concordance for the three biomarkers with lymph node 
metastases. Baldus et al. [15] studied 100 patients and 
found major discordances in primary tumor versus 
lymph node metastases, whereby 17 out of 55 patients 
(31%) whose KRAS mutation profile was examined had 
a discordant result. This heterogeneity was also found in 
4% and 13% of cases for BRAF and PIK3CA, respectively. 
As we have previously shown with FISH and high-density 
single-nucleotide polymorphism (SNP) array techniques 
[17], the metastases from an individual with mCRC are 
extremely similar to each other but are divergent from 
the paired primary tumor. Particular clonal genetic events 
present in the metastasis samples can also be found in 
restricted subclones of the primary tumor, suggesting 
that only some tumor cells within the primary tumor have 
the ability to metastasize, as is sometimes observed in 
human medulloblastoma [33]. Another explanation for 
our findings is that the primary tumor may have been 
reseeded by a metastatic clone that had experienced 
additional genetic events at the periphery. In our series, 
mutations of the KRAS gene were more frequent in liver 
metastases (36%) than in primary tumors (16%). The 
greater incidence of KRAS mutations in liver metastases 
implies that they are acquired mutations. There is a 
general consensus that cancer progression arises from a 
single mutated cell, followed by a clonal expansion 
associated with genetic alterations. The acquisition of 
these alterations can result in the emergence of new tumor 
subclones with different genotypes. In this context, we 
observed that 13 out of 16 WT primary tumors did not 
change their molecular profile during disease progression, 
which means that it is more likely that WT primary tumors 
will not clonally evolve. This may be because they are 
made up of a single non-mutated clone and are genetically 
stable; several studies have examined prognostic 
markers of outcome after liver resection for colorectal 
cancer metastases and concluded that genetic stability 
is associated with a better outcome [34]. In addition, we 
observed that in 5 of the 11 cases showing linear clonal 
evolution between the primary tumor and the lymph node 
metastasis, four were WT clones. As previously discussed 
[15, 32], the lower incidence of mutations in lymph node 
metastases indicates that these metastases are caused 
by tumor clones that escape from the primary tumor in 
the early stages of the disease, before KRAS or other 
mutations occur. In addition, clonal selection during the 
metastatic process is noted, since the mutations in PIK3CA 
are not observed during tumor progression (only two cases 
had acquired PIK3CA mutations in liver metastases). 
Clones with mutated KRAS are observed from the outset 
or during the metastatic process. It is well known that 
RAS and BRAF mutations are mutually exclusive [35], but 
our study shows that the presence of either a KRAS or a 
BRAF mutation in primary tumor or at metastatic sites, 
does not preclude the presence of the other mutation in 
a different location. The presence of distinct mutations 
among samples of the same patient suggests that there 
might be different tumor clones in a primary tumor and as 
the disease progresses the mutational profile of the clones 
is modified.
Since only KRAS and NRAS mutations preclude 
patients from being treated with EGFR inhibitors, and 
in clinical practice most mutational status studies are 
performed in primary tumors [8], in our series, 20 of 
the 26 patients would have been classified as WT, and 
thereby candidates for anti-EGFR treatments. Of these 
20 WT primary tumor patients, five had mutations in 
KRAS or NRAS in lymph nodes or liver metastases, which 
means that if only primary tumors had been analyzed 
when looking for mutations in KRAS and NRAS, five 
mutant, EGFR inhibitor-resistant cases would have been 
misdiagnosed. The presence of different tumor clones in 
a primary malignancy and at its metastatic sites, along 
with clonal evolution in sCRC might explain why some 
patients do not respond to EGFR inhibitors, and confirm 
the utility of evaluating KRAS and NRAS mutations not 
only in primary tumors, but also at all metastatic sites.
In summary, in this study we confirm the presence 
of different mutational profiles in primary tumors, lymph 
node metastases and liver metastases. We believe that 
the presence of acquired mutations in genes involved in 
the EGFR pathway at metastatic sites could explain why 
not all patients respond to EGFR. These results highlight 
the need to analyze the mutations in all available tumoral 
samples of the patient before deciding upon anti-EGFR 
treatment. Larger studies assessing the therapeutic impact 
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of the mutation portrait detected in the different tumor 
samples of the same patient are needed.
MATERIALS AND METHODS
Patients and samples
Tissue specimens from 26 sporadic colorectal 
carcinomas, 16 paired lymph node metastases and 34 
paired liver metastases (n=76 samples) were obtained 
from 26 patients (19 males and 7 females) before any 
systemic treatment or local radiotherapy was given. The 
median age was 67 years (range, 48-79 years). All patients 
had undergone surgical resection of tumor tissues (primary 
tumors, metastatic lymph nodes and liver metastases) at 
the Department of Surgery of the University Hospital of 
Salamanca (Salamanca, Spain) between 2000 and 2013, 
and they were recruited into the study after they had given 
their informed consent to participate. The study underwent 
institutional review and was approved by the Local Ethics 
Committee of the University Hospital of Salamanca 
(Salamanca, Spain).
Salient clinical and laboratory data of the 26 patients 
studied are fully described in Table 1 and summarized 
in Supplementary Table 1. All tumors were diagnosed 
and classified according to the WHO criteria [36] and 
staged according to the TNM Classification of Malignant 
Tumours (6th edition) [37]. By tumor grade, there were 16, 
8 and 2 cases of well, moderately and poorly differentiated 
carcinomas. The histopathological grade of all tumors 
was confirmed in a second independent evaluation by an 
experienced pathologist.
Eleven primary tumors were localized in the rectum 
and the other 15 were in the right (caecum, ascending or 
transverse) or left (descending or sigmoid) colon. The 
median size of the primary tumors was 5.3 cm (range, 2.5-
9.0 cm) with the following distribution by TNM stage: 
T2N0M0, 1 tumor; T3N0M0, 1; T3N0M1, 4; T3N1M0, 
2; T3N1M1, 8; T3N2M0, 1; T3N2M1, 3; T4N0M0, 1; 
T4N0M1, 2; T4N1M1, 1; and; T4N2M1, 2 tumors. Paired 
liver metastases were identified at the time of colorectal 
surgery or during the first year after initial diagnosis 
(n=25); the mean size of the largest liver metastases was 
4.0 cm (range, 0.5-10.0 cm).
Once the histopathological diagnosis had been 
established, sections from paraffin-embedded tissue 
samples were cut from three representative areas of 
the tumor tissue with >70% tumor cell infiltration as 
established by hematoxylin-eosin staining, after excluding 
stroma-enriched tumor areas. In order to enrich the tumor 
cells, the neighboring areas of those containing ≥70% 
tumor cells were then microdissected from the paraffin-
embedded tumor tissue samples by an experienced 
pathologist. DNA was extracted and isolated using a 
Maxwell® 16 System for Genomic DNA Extraction 
(Promega, Mannheim, Germany) and quantified using a 
Qubit dsDNA BR assay (Invitrogen, Life Technologies, 
CA, USA).
Mutational analysis using low-density 
microarray technology
After the histopathological diagnosis, primary 
tumor, lymph node metastasis and paired liver metastasis 
of each patient were tested for mutations in the KRAS, 
NRAS, BRAF and PI3K genes using a multiplex allele-
specific PCR-based assay, which assesses 44 mutations in 
KRAS codons 12, 13, 59, 61, 117 and 146 (G12A, G12C, 
G12D, G12R, G12S, G12V, G13D, A59E, A59G, A59T, 
Q61K (C>A), Q61K (C>AA), Q61L, Q61R, Q61H(A>T), 
Q61H(A>C), K117N(A>C), K117(A>T), A146P, A146V, 
and A146T), NRAS codons 12, 13, 59, 61, 117 and 146 
(G12D, G12C, G12S, G12A, G12V, G13D, G13R, G13V, 
A59T, Q61K, Q61R, Q61L, Q61H(A>C), Q61H(A>T), 
K117N(G>C), K117N(G>T), A146T and A146V)) and 
BRAF codon 600 (V600E(T>A), V600E(G>AA), V600D, 
V600K and V600R). A total of 76 assays (26 primary 
tumors, 16 lymph node metastases and 34 liver metastases) 
were performed using two kits based on polymerase 
chain reaction amplification and array hybridization 
with different probes, following the manufacturer’s 
instructions (CLART® CMA·KRAS·BRAF·PIK3CA 
and CLART CMA·NRAS·iKRAS kits; Genomica SAU 
Technology, Madrid, Spain). Estimated sensitivity was 1% 
as established by the manufacturer.
Patient and public involvement
This study analysed cancer tissues from de-linked 
database. Therefore, we did not inform or disseminate 
to patients the research question, the outcome measures 
and the results. Patients were not involved in the study, 
including in the design, recruitment and conduct of 
the study. No patient adviser was included in the 
contributorship statement.
Statistical methods
Means, standard deviations (SDs) and ranges of 
continuous variables, and the frequencies and percentages 
of dichotomous variables were calculated using IBM 
SPSS for Windows version 20.0 (IBM Corp., Armonk, 
NY, USA).
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Oncotarget34286www.oncotarget.com
CONFLICTS OF INTEREST
The authors declared no potential conflicts of 
interest with respect to the research, authorship, and/or 
publication of this article.
FUNDING
This work has been partially supported by grants 
from the Instituto de Salud Carlos III (ISCIII; Ministerio 
de Sanidad y Consumo, Madrid, Spain) (PI18/00282), the 
Gerencia Regional de Salud de Castilla y León, Valladolid, 
Spain (GRS1302/A/16), the RTICC of the ISCIII 
(RD12/0020/0035-FEDER, RD12/0036/0048-FEDER) 
and CIBERONC (CB16/12/00400 and CB16/12/00233), 
the Fundación Memoria de Don Samuel Solórzano 
Barruso (Salamanca, Spain) and the Fundación Eugenio 
Rodríguez Pascual, (Madrid, Spain). JM Sayagués and 
ME Sarasquete are supported by grants (CES11/004 and 
CP13/00080) from the ISCIII, Ministerio de Ciencia e 
Innovación, Madrid, Spain.
REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, 
Rebelo M, Parkin DM, Forman D, Bray F. Int J Cancer. 
2015; 136:E359-86. https://doi.org/10.1002/ijc.29210.
2. Parkin DM. Global cancer statistics in the year 2000. 
Lancet Oncol. 2001; 2:533-543. https://doi.org/10.1016/
S1470-2045(01)00486-7.
3. Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang 
K, Williams R, Wiezorek J. Mutant KRAS codon 12 and 
13 alleles in patients with metastatic colorectal cancer: 
assessment as prognostic and predictive biomarkers of 
response to panitumumab. J Clin Oncol. 2013; 31:759-765. 
https://doi.org/10.1200/JCO.2012.45.1492.
4. De Roock W, De Vriendt V, Normanno N, Ciardiello F, 
Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: 
Implications for targeted therapies in metastatic colorectal 
cancer. Lancet Oncol. 2011; 12:594-603. https://doi.
org/10.1016/S1470-2045(10)70209-6.
5. Rowland A, Dias MM, Wiese MD, Kichenadasse G, 
McKinnon RA, Karapetis CS, Sorich MJ. Meta-analysis of 
BRAF mutation as a predictive biomarker of benefit from 
anti-EGFR monoclonal antibody therapy for RAS wild-type 
metastatic colorectal cancer. Br J Cancer. 2015; 112:1888-
1894. https://doi.org/10.1038/bjc.2015.173.
6. De Roock W, Claes B, Bernasconi D, De Schutter J, 
Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, 
Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier 
P, Vincenzi B, et al. Effects of KRAS, BRAF, NRAS, 
and PIK3CA mutations on the efficacy of cetuximab plus 
chemotherapy in chemotherapy-refractory metastatic 
colorectal cancer: A retrospective consortium analysis. 
Lancet Oncol. 2010; 11:753-762. https://doi.org/10.1016/
S1470-2045(10)70130-3.
7. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, 
Gevorgyan A, Losa M, Frattini M, Riva C, Andreola 
S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S. 
PI3KCA/PTEN deregulation contributes to impaired 
responses to cetuximab in metastatic colorectal cancer 
patients. Ann Oncol. 2009; 20:84-90. https://doi.
org/10.1093/annonc/mdn541.
8. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van 
Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, 
Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio 
E, et al. ESMO consensus guidelines for the management of 
patients with metastatic colorectal cancer. Ann Oncol. 2016; 
27:1386-422. https://doi.org/10.1093/annonc/mdw235.
9. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan 
CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro 
JD, Robitaille S, Price TJ, Shepherd L, Au HJ, et al. 
K-ras mutations and benefit from cetuximab in advanced 
colorectal cancer. N Engl J Med. 2008; 359:1757-65. 
https://doi.org/10.1056/NEJMoa0804385.
10. Tian S, Simon I, Moreno V, Roepman P, Tabernero J, 
Snel M, van't Veer L, Salazar R, Bernards R, Capella G. 
A combined oncogenic pathway signature of BRAF, 
KRAS and PI3KCA mutation improves colorectal 
cancer classification and cetuximab treatment prediction. 
Gut. 2013; 62:540-549. https://doi.org/10.1136/
gutjnl-2012-302423.
11. Losi L, Benhattar J, Costa J. Stability of K-ras mutations 
throughout the natural history of human colorectal cancer. 
Eur J Cancer. 1992; 28A:1115-20.
12. Zauber P, Sabbath-Solitare M, Marotta SP, Bishop DT. 
Molecular changes in the Ki-ras and APC genes in primary 
colorectal carcinoma and synchronous metastases compared 
with the findings in accompanying adenomas. Mol Pathol. 
2003; 56:137-140.
13. Etienne-Grimaldi MC, Formento JL, Francoual M, 
François E, Formento P, Renée N, Laurent-Puig P, Chazal 
M, Benchimol D, Delpero JR, Letoublon C, Pezet D, 
Seitz JF, Milano G. K-Ras mutations and treatment 
outcome in colorectal cancer patients receiving exclusive 
fluoropyrimidine therapy. Clin Cancer Res. 2008; 14:4830-
4835. https://doi.org/10.1158/1078-0432.CCR-07-4906.
14. Albanese I, Scibetta AG, Migliavacca M, Russo A, Bazan 
V, To masino RM, Colomba P, Tagliavia M, La Farina 
M. Heterogeneity within and between primary colorectal 
carcinomas and matched metastases as revealed by analysis 
of Ki-ras and p53 mutations. Biochem Biophys Res 
Commun. 2004; 325:784-791.
15. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein 
NH, Gabbert HE. Prevalence and heterogeneity of KRAS, 
BRAF, and PIK3CA mutations in primary colorectal 
adenocarcinomas and their corresponding metastases. 
Clin Cancer Res. 2010; 16:790-799. https://doi.
org/10.1158/1078-0432.CCR-09-2446.
Oncotarget34287www.oncotarget.com
16. Al-Mulla F, Going JJ, Sowden ET, Winter A, Pickford 
IR, Birnie GD. Heterogeneity of mutant versus wild-type 
Ki-ras in primary and metastatic colorectal carcinomas, 
and association of codon-12 valine with early mortality. J 
Pathol. 1998; 185:130-138.
17. Sayagués JM, Abad Mdel M, Melchor HB, Gutiérrez ML, 
González-González M, Jensen E, Bengoechea O, Fonseca 
E, Orfao A, Muñoz-Bellvis L. Intratumoural cytogenetic 
heterogeneity of sporadic colorectal carcinomas suggests 
several pathways to liver metastasis. J Pathol. 2010; 
221:308-319. https://doi.org/10.1002/path.2712.
18. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki 
MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, 
Tejpar S, Schlichting M, Zubel A, Celik I, et al. Cetuximab 
plus irinotecan, fluorouracil, and leucovorin as first-line 
treatment for metastatic colorectal cancer: updated analysis 
of overall survival according to tumor KRAS and BRAF 
mutation status. J Clin Oncol. 2011; 29:2011-2019. https://
doi.org/10.1200/JCO.2010.33.5091.
19. Shaib W, Mahajan R, El-Rayes B. Markers of resistance 
to anti-EGFR therapy in colorectal cancer. J Gastrointest 
Oncol. 2013; 4:308-318. https://doi.org/10.3978/j.
issn.2078-6891.2013.029.
20. Iwasa Y, Michor F. Evolutionary dynamics of intratumor 
heterogeneity. PLoS One. 2011; 6:e17866. https://doi.
org/10.1371/journal.pone.0017866.
21. McGranahan N, Swanton C. Biological and therapeutic 
impact of intratumor heterogeneity in cancer evolution. 
Cancer Cell. 2015; 27:15-26. https://doi.org/10.1016/j.
ccell.2014.12.001.
22. Turtoi A, Blomme A, Castronovo V. Intratumoral 
heterogeneity and consequences for targeted therapies. 
Bull Cancer. 2015; 102:17-23. https://doi.org/10.1016/j.
bulcan.2014.12.006.
23. Normanno N, Rachiglio AM, Lambiase M, Martinelli 
E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, 
Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F; 
CAPRI-GOIM investigators. Heterogeneity of KRAS, 
NRAS, BRAF and PIK3CA mutations in metastatic 
colorectal cancer and potential effects on therapy in the 
CAPRI GOIM trial. Ann Oncol. 2015; 26:1710-1714.
https://doi.org/10.1093/annonc/mdv176.
24. Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani 
T, Pisconti S, Giuliani F, Barone C, Cartenì G, Rachiglio 
AM, Montesarchio V, Tonini G, Rizzi D, et al. Clinical 
activity of FOLFIRI plus cetuximab according to extended 
gene mutation status by next-generation sequencing: 
findings from the CAPRI-GOIM trial. Ann Oncol. 2014; 
25:1756-61. https://doi.org/10.1093/annonc/mdu230.
25. Brannon AR, Vakiani E, Sylvester BE, Scott SN, 
McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, 
Vacic V, Emde AK, Cercek A, Yaeger R, et al. Comparative 
sequencing analysis reveals high genomic concordance 
between matched primary and metastatic colorectal 
cancer lesions. Genome Biol. 2014; 15:454. https://doi.
org/10.1186/s13059-014-0454-7.
26. Mao C, Wu XY, Yang ZY, Threapleton DE, Yuan JQ, 
Yu YY, Tang JL. Concordant analysis of KRAS, BRAF, 
PIK3CA mutations, and PTEN expression between primary 
colorectal cancer and matched metastases. Sci Rep. 2015; 
5:8065. https://doi.org/10.1038/srep08065.
27. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, 
Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, 
Patterson SD, Chang DD. Wild-type KRAS is required for 
panitumumab efficacy in patients with metastatic colorectal 
cancer. J Clin Oncol. 2008; 26:1626-1634. https://doi.
org/10.1200/JCO.2007.14.7116.
28. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, 
Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland 
AH, Wilson G, Ciuleanu TE, et al. Randomized Phase III 
Study of Panitumumab With Fluorouracil, Leucovorin, and 
Irinotecan (FOLFIRI) Compared With FOLFIRI Alone 
As Second-Line Treatment in Patients With Metastatic 
Colorectal Cancer. J Clin Oncol. 2010; 28:4706-4713. 
https://doi.org/10.1200/JCO.2009.27.6055.
29. Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, 
Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, 
van Krieken JH, Punt CJ, Nagtegaal ID. KRAS mutation 
analysis: a comparison between primary tumours and 
matched liver metastases in 305 colorectal cancer patients. 
Br J Cancer. 2011; 104:1020-1026. https://doi.org/10.1038/
bjc.2011.26.
30. Jeantet M, Tougeron D, Tachon G, Cortes U, Archambaut 
C, Fromont G, Karayan-Tapon L. High Intra- and Inter-
Tumoral Heterogeneity of RAS Mutations in Colorectal 
Cancer. Int J Mol Sci. 2016; 17. https://doi.org/10.3390/
ijms17122015.
31. Kosmidou V, Oikonomou E, Vlassi M, Avlonitis S, Katseli 
A, Tsipras I, Mourtzoukou D, Kontogeorgos G, Zografos 
G, Pintzas A. Tumor heterogeneity revealed by KRAS, 
BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA 
intratumor mutation profile differences and their therapeutic 
implications. Hum Mutat. 2014; 35:329-340. https://doi.
org/10.1002/humu.22496.
32. Miranda E, Bianchi P, Destro A, Morenghi E, Malesci A, 
Santoro A, Laghi L, Roncalli M. Genetic and epigenetic 
alterations in primary colorectal cancers and related lymph 
node and liver metastases. Cancer. 2013; 119:266-276. 
https://doi.org/10.1002/cncr.27722.
33. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H, 
Croul S, Bouffet E, Fults DW, Eberhart CG, Garzia L, Van 
Meter T, Zagzag D, et al. Clonal selection drives genetic 
divergence of metastatic medulloblastoma. Nature. 2012; 
482:529-533. https://doi.org/10.1038/nature10825.
34. Løes IM, Immervoll H, Sorbye H, Angelsen JH, Horn 
A, Knappskog S, Lønning PE. Impact of KRAS, BRAF, 
PIK3CA, TP53 status and intraindividual mutation 
heterogeneity on outcome after liver resection for colorectal 
Oncotarget34288www.oncotarget.com
cancer metastases. Int J Cancer. 2016; 139:647-656. https://
doi.org/10.1002/ijc.30089.
35. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, 
Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS 
oncogenes and mismatch-repair status. Nature. 2002; 
418:934.
36. The International Agency for Research on Cancer. 
Pathology and Genetics of Tumours of the Digestive 
System. Pathology and Genetics of Tumours of the 
Digestive System. WHO Classification of Tumours, 3rd 
Edition, Volume 2. Hamilton SR, Aaltonen LA (eds). 2006; 
16:8-3.
37. International Union Against Cancer. TNM Classification 
of Malignant Tumours. Sobin LH, Gospodarowicz MK, 
Wittekind C (eds). 2002; 10.
